两种抗VEGF药物治疗渗出性年龄相关性黄斑病变的疗效

Efficacy of two anti-VEGF drugs for age-related macular degeneration

目的:观察雷珠单抗和康柏西普治疗湿性年龄相关性黄斑变性的临床疗效。方法:回顾性病例系列研究。分析30例30眼雷珠单抗玻璃体腔注射0.5mg每月1次,连续3次治疗湿性老年黄斑变性的病例和28例30眼康柏西普玻璃体腔注射0.5mg每月1次,连续3次治疗湿性老年黄斑变性的病例,比较两组分别在玻璃体腔注药1mo后的最佳矫正视力及OCT变化情况。结果:连续3次玻璃体腔注药,每次治疗后1mo与治疗前相比,A组BCVA平均值提高,CMT平均值降低,差异具有统计学意义(P<0.05);B组BCVA平均值提高,CMT平均值亦降低,差异具有统计学意义(P<0.05),两组间比较BCVA变化、CMT变化差异不具有统计学意义(P>0.05)。结论:雷珠单抗和康柏西普治疗均能有效控制湿性AMD患者病情发展并改善视力,治疗3mo内两种药物疗效的比较无统计学意义。

AIM： To evaluate efficacy of Ranibizumab and Conbercept for wet age-related m acular degeneration（ wAMD）.METHODS： This was a retrospective case series study.Thirty patients（ 30 eyes） with wAMD were enrolled to receive intravitreal injections of ranibizum ab（ 0. 5m g） on3 consecutive m onthly schedule and 28 patients（ 30 eyes）with wAMD were enrolled to receive intravitreal injections of conbercept（ 0. 5m g） on 3 consecutive m onthly schedule. Best corrected visual acuity（ BCVA）, optic coherence tom ography（ OCT） m easurem ent were com pared at 1m o after injections.RESULTS： One month after every injection,the BCVA increased while the central m acular thickness（ CMT）decreased com pared with those before treatm ent in group A and B（ P〈0. 05）. BCVA and CMT changes between two groups were no statistically different（ P〉0. 05）.CONCLUSION： Ranibizumab and conbercept therapy can control the prognosis of wAMD and im prove the vision effectively. There is no statistical difference on the curative effect between two drugs for 3mo.